Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,184 recruiting studies in this area right now.
By phase
- Not applicable2,936
- Phase 2755
- Phase 1540
- Phase 3382
- Phase 1/Phase 2297
- Phase 4211
- Phase 2/Phase 363
Top conditions
- Breast Cancer1,226
- Melanoma183
- Rheumatoid Arthritis142
- Metastatic Breast Cancer140
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Breast Neoplasms120
- Triple Negative Breast Cancer117
- Colorectal Cancer93
- Ovarian Cancer92
- Psoriasis88
- Breast Carcinoma83
- Lung Cancer79
- Prostate Cancer70
- Rheumatoid Arthritis (RA)65
- Diabetic Foot Ulcer61
- Systemic Sclerosis60
- Cancer58
Leading sponsors
- Fudan University66
- M.D. Anderson Cancer Center52
- Memorial Sloan Kettering Cancer Center50
- Novartis Pharmaceuticals47
- Mayo Clinic42
- Assistance Publique - Hôpitaux de Paris41
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University37
- AstraZeneca36
- National Cancer Institute (NCI)35
- Second Affiliated Hospital, School of Medicine, Zhejiang University30
Where studies are running
- California421
- Arizona159
- Florida131
- Alabama127
- New York109
- Texas107
- Massachusetts93
- Maryland91
- Pennsylvania75
- North Carolina68
Recruiting studies5,184 total
- NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT05369546Recruiting
Imaging study for suspicious breast findings
This study looks at how detailed breast imaging can help diagnose breast cancer when a mammogram is suspicious. If your mammogram result was “highly suspicious” and you have not had a biopsy yet, the trial may be able to use your images to improve future diagnosis.
Tampa, FloridaAges 20–85 - NCT05371613RecruitingPhase 2/Phase 3
Testing tividenofusp alfa vs idursulfase for MPS II
This trial compares a new treatment (tividenofusp alfa) to the current standard treatment (idursulfase) in children and young adults with MPS II. It’s looking to see which option works better and is safe, especially based on age and whether the disease affects the brain.
Oakland, CaliforniaAges 2–25 - NCT05371353Recruiting
Study of how long HPV vaccine immunity lasts
This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.
Yangchun, GuangdongAges 9–45 - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05373823Recruiting
Online skin check coaching for melanoma survivors
This study tests an online program to help melanoma survivors do full-body skin self-checks regularly. It may help you catch new or changing skin areas earlier by improving how often and how thoroughly you check.
New Brunswick, New JerseyAges 18 years+ - NCT05377047Recruiting
Targeted radiation for limited recurrent breast cancer spread
This trial tests whether a precise form of high-dose radiation can control up to 1–5 breast cancer metastases (spread) in a few body areas. It may help by focusing treatment only on visible spots while limiting radiation to the rest of the body.
Gothenburg, Västra GötalandsregionenAges 18 years+ - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05381038RecruitingPhase 1/Phase 2
Personalized azacitidine combinations for breast or stomach cancer
This Phase 1/2 trial tests different combinations that include azacitidine, chosen based on your tumor’s lab “response markers” and past drug-sensitivity screening. It aims to find safer dosing and see whether these personalized combinations can shrink solid tumors such as breast or stomach cancer.
SingaporeAges 21–99 - NCT05386108RecruitingPhase 1/Phase 2
Test abemaciclib plus elacestrant for breast cancer brain spread
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
Fullerton, CaliforniaAges 18 years+ - NCT05386719Recruiting
Cardiometabolic screening for people after early breast cancer
This trial tests a screening program to look for heart- and metabolism-related health risks in people who have completed treatment for early breast cancer. It may help catch problems earlier so you can get timely care.
Baltimore, MarylandAges 18 years+ - NCT05388149RecruitingPhase 2
Neratinib plus Kadcyla to treat leftover HER2 breast cancer
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Toronto, OntarioAges 18 years+ - NCT05389332Recruiting
Mobile WhatsApp program to help reduce skin cancer risk
This trial tests a mobile phone health program (using WhatsApp) to help Hispanic adults lower their risk of skin cancer. It focuses on encouraging better sun protection and checking your skin regularly.
New Brunswick, New JerseyAges 18–100 - NCT05391100Recruiting
Screening people with rheumatoid arthritis for lung scarring
This study looks for early lung scarring in people who have rheumatoid arthritis. It may help find a serious lung condition earlier so doctors can watch or treat it sooner.
BudapestAges 40 years+ - NCT05391061Recruiting
Cibinqo tablet study for moderate-to-severe atopic dermatitis
This study looks at Cibinqo (an oral medicine) in people with moderate-to-severe atopic dermatitis (eczema) who are already going to start it under their clinician’s standard care plan. It may help doctors learn about how the medicine works and fits into real-world treatment.
SeoulAges 12 years+ - NCT05394922Recruiting
Study of sugar patterns in lupus anti-DNA antibodies
This study looks at the “sugar coating” on anti-DNA antibodies in people with lupus. The goal is to better understand these antibody patterns, which may help improve how lupus is studied or treated in the future.
MontpellierAges 18–80 - NCT05396612Recruiting
Studying the immune response in non-cancer-spread breast surgery
This study looks at how your immune system changes while you receive standard breast cancer treatment around the time of surgery. The goal is to learn why some people respond better than others, which could help future treatment choices.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05398809RecruitingPhase 2
Ruxolitinib for hair regrowth in APECED-related alopecia areata
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
Bethesda, MarylandAges 12–75 - NCT05399433Recruiting
Studying how sugar metabolism affects immune skin cells in psoriasis
This study looks at how blood sugar control (including diabetes) changes immune cells in the skin for people with moderate to severe plaque psoriasis. It may help researchers understand what drives psoriasis and how it could respond to future treatments.
Nice, Alpes-maritimesAges 18–80 - NCT05403177Recruiting
Share your cancer data and samples for Ontario research
This study collects and combines medical records, genetic (genomic) data, and tumor/blood samples from people with cancer. It helps researchers build and improve a large “gold standard” cancer dataset that can support future studies and better understanding of cancer.
Kingston, OntarioAges 18 years+ - NCT05403710Recruiting
Botox injections for people with hidradenitis suppurativa
This trial studies whether botulinum toxin (Botox) injections can improve hidradenitis suppurativa (HS), a painful skin condition with recurring bumps and tunnels. You might be a good match if you have long-lasting HS in more than one body area and can safely do skin-area treatment visits (including skin biopsy if needed).
Worcester, MassachusettsAges 18–75 - NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT05404321Recruiting
Collecting tumor samples to study triple-negative breast cancer treatments
This study collects tumor tissue from people with early-stage triple-negative breast cancer before they start neoadjuvant chemotherapy. The goal is to help researchers test new therapies and look for markers that may predict who benefits.
CaenAges 18 years+
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,184 recruiting dermatology studies from the U.S. registry right now, out of 8,288 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.